Europe Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

List of Tables

The Europe glioma treatment market is expected to grow from US$ 959.99 million in 2022 to US$ 1,905.10 million by 2030. It is estimated to grow at a CAGR of 8.9% from 2022 to 2030.

Increase in Prevalence of High-Grade Glioma Fuels Europe Glioma Treatment Market

High-grade gliomas include aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. These tumors are characterized by their rapid growth, infiltrative behavior, and resistance to conventional treatment methods. High-grade gliomas are multifaceted tumors that are not yet fully understood, which is a major reason for their increasing incidence. Moreover, aging populations, environmental exposure, genetic predispositions, and improved diagnostic capabilities are other notable factors that result in a large number of cases. Gliomas, particularly glioblastomas, are known for their devastating impact on patients\' lives due to their location within the brain and ability to disrupt critical neurological functions.

The most frequent and dangerous type of brain tumor is glioblastoma. Globally, more than 250,000 new cases of primary malignant brain tumors are detected each year, with gliomas accounting for 77% of these occurrences. It still remains a rare disease, accounting for over 50% of primary malignant brain tumors.

Europe Glioma Treatment Market Overview

The Europe glioma treatment market in Europe is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. The region holds the second-largest share of the global market, which can be attributed to the increasing number of brain tumor cases, technological advancements in brain tumor treatments in France, the increasing prevalence of neurological disorders in the UK, and surging healthcare investments in Germany. The healthcare sector in the UK has access to well-developed advanced medical technologies and devices. According to the United Kingdom National Health Service, more than 11,000 people are diagnosed with brain tumors in the UK each year, of which nearly 50% of tumors are cancerous. Per the Globocan 2020 data, the UK recorded about 7,697 new cases of brain and central nervous system cancer. As a result of the burgeoning incidence, several private and government organizations are investing in cancer research. As per the written evidence related to brain tumor and childhood cancer research from Cancer Research UK (BCCR0001), released in April 2021, Cancer Research UK has committed USD 35.45 million since 2018 to encourage brain tumor research through funding calls for brain tumor research and launching centers of excellence and a radiation research network. The center invested USD15.20 million in brain tumor research, and USD 11.12 million in cancer research affecting children and adolescents in 2019-2020 to become one of the largest research funders in the field of brain tumors across the UK.

Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Glioma Treatment Market Segmentation

The Europe glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Europe glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Europe glioma treatment market in 2022.

Based on treatment type, the Europe glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Europe glioma treatment market in 2022.

Based on grade, the Europe glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Europe glioma treatment market in 2022.

Based on end user, the Europe glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Europe glioma treatment market in 2022.

Based on country, the Europe glioma treatment market is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. Germany dominated the Europe glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Europe glioma treatment market.

Product Code: BMIRE00029267

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Government Funding for Glioma Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - Europe Market Analysis

5.1 Europe Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 Europe Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 Europe Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 Europe Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Europe Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Glioma Treatment Market - Country Analysis

10.1 Overview
- 10.1.1 Europe Glioma Treatment Market, by Country
  - 10.1.1.1 UK
    - 10.1.1.1.1 UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.1.2 UK: Europe Glioma Treatment Market, by Disease
    - 10.1.1.1.3 UK: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.1.4 UK: Europe Glioma Treatment Market, by Grade
    - 10.1.1.1.4.1 UK: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.1.4.2 UK: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.1.5 UK: Europe Glioma Treatment Market, by End User
  - 10.1.1.2 Germany
    - 10.1.1.2.1 Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Germany: Europe Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Germany: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Germany: Europe Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Germany: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Germany: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Germany: Europe Glioma Treatment Market, by End User
  - 10.1.1.3 France
    - 10.1.1.3.1 France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 France: Europe Glioma Treatment Market, by Disease
    - 10.1.1.3.3 France: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 France: Europe Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 France: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 France: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 France: Europe Glioma Treatment Market, by End User
  - 10.1.1.4 Italy
    - 10.1.1.4.1 Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.4.2 Italy: Europe Glioma Treatment Market, by Disease
    - 10.1.1.4.3 Italy: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.4.4 Italy: Europe Glioma Treatment Market, by Grade
    - 10.1.1.4.4.1 Italy: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.4.4.2 Italy: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.4.5 Italy: Europe Glioma Treatment Market, by End User
  - 10.1.1.5 Spain
    - 10.1.1.5.1 Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.5.2 Spain: Europe Glioma Treatment Market, by Disease
    - 10.1.1.5.3 Spain: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.5.4 Spain: Europe Glioma Treatment Market, by Grade
    - 10.1.1.5.4.1 Spain: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.5.4.2 Spain: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.5.5 Spain: Europe Glioma Treatment Market, by End User
  - 10.1.1.6 Rest of Europe
    - 10.1.1.6.1 Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.6.2 Rest of Europe: Europe Glioma Treatment Market, by Disease
    - 10.1.1.6.3 Rest of Europe: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.6.4 Rest of Europe: Europe Glioma Treatment Market, by Grade
    - 10.1.1.6.4.1 Rest of Europe: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.6.4.2 Rest of Europe: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.6.5 Rest of Europe: Europe Glioma Treatment Market, by End User

11. Europe Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Sun Pharmaceutical Industries Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Amgen Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Teva Pharmaceutical Industries Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Pfizer Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Amneal Pharmaceuticals Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Karyopharm Therapeutics Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Biocon Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms